The Ruth Rappaport Children’s Hospital, located within Rambam Health Care Campus (Rambam), is the only dedicated pediatric hospital in Northern Israel, providing advanced, comprehensive care for children from birth to age 18. Rambam is a 1,100-bed academic medical center serving more than 2.7 million residents and is the region’s sole tertiary referral hospital, providing comprehensive care across all medical specialties to patients referred from 12 district hospitals and regional defense forces.
Established in 1986 and affiliated with the Technion – Israel Institute of Technology’s Ruth and Bruce Rappaport Faculty of Medicine, the Ruth Rappaport Children’s Hospital serves as a center of excellence in pediatric care, education, and research. As part of Rambam’s internationally recognized medical and research environment, its multidisciplinary teams collaborate globally to advance innovative treatments and ensure the highest standard of care for children across Northern Israel.
The Joan & Sanford Weil Division of Pediatric Hematology-Oncology and Bone Marrow Transplantation at the Ruth Rappaport Children’s Hospital provides specialized care for children and adolescents up to age 20 with cancer and blood disorders, including bone marrow transplantation. As the only division of its kind in Northern Israel, it diagnoses and treats over 120 new patients a year and achieves cure rates of approximately 80%, comparable to leading pediatric cancer centers in Europe and the United States. The Division delivers multidisciplinary care aligned with international protocols, including comprehensive psychological and supportive services for patients and families, as well as long-term follow-up for survivors. In parallel, its physician-scientists lead innovative research and clinical trials in collaboration with the Technion, advancing new treatments and improving outcomes for children in Israel and beyond.
Research Team
Dr. Arad-Cohen is Director of the Division of Pediatric Hematology, Oncology, and Bone Marrow Transplantation at the Ruth Rappaport Children’s Hospital at Rambam Health Care Campus. A graduate of the Technion – Israel Institute of Technology Faculty of Medicine, she completed her residency in Pediatrics at Carmel Medical Center and her fellowship in Pediatric Hematology-Oncology at Rambam, both with honors.
An internationally recognized leader in pediatric leukemia, Dr. Arad-Cohen has led Rambam’s pediatric leukemia program since 2009 and was appointed Israel’s national lead for pediatric acute myeloid leukemia (AML) in 2014. She serves on the international steering committee responsible for developing and implementing treatment protocols for pediatric AML and chairs its Supportive Care Working Group within the NOPHO-DB-SHIP consortium. Her leadership has contributed to significant improvements in survival outcomes for children in Israel.
Dr. Arad-Cohen is also a Clinical Lecturer at the Technion and has authored more than 30 peer-reviewed publications. She has led innovative initiatives to improve patient care, including the development of a digital application to support children with leukemia and their families. She is an active member of national and international professional societies and has received multiple awards recognizing her clinical excellence and leadership.
Dr. Mordechai is Deputy Director of the Division of Pediatric Hematology, Oncology, and Bone Marrow Transplantation at Rambam Health Care Campus. He is board certified in Pediatrics and Pediatric Hematology-Oncology and earned his medical degree from Ben-Gurion University of the Negev, along with a Master of Public Health and additional training in biomedical computation. He completed a research fellowship in cancer genetics at the Broad Institute of MIT and Harvard in Cambridge, Massachusetts, focusing on cancer genomics and precision oncology.
Dr. Mordechai leads the Solid Tumor Program and the Pediatric Oncogenetics Service at Rambam. His clinical and research work centers on sarcoma, hepatoblastoma, cancer genomics, and early-phase clinical trials for children with refractory and relapsed solid tumors. He serves as Rambam’s Principal Investigator within the European ITCC (Innovative Therapies for Children with Cancer) consortium and is a board member of the Israeli Society of Pediatric Hematology-Oncology. His work integrates genomic profiling and artificial intelligence-based tools to advance precision medicine and supportive care in pediatric oncology.